Linearity of β-cell response across the metabolic spectrum and to pharmacology: Insights from a graded glucose infusion-based investigation series

American Journal of Physiology - Endocrinology and Metabolism

Volumn 310, Issue 11, 2016, Pages E865-E873

  Shankar, Sudha S ^a   Shankar, R Ravi ^a   Mixson, Lori A ^a   Miller, Deborah L ^a   Chung, Christopher ^a   Cilissen, Caroline ^b   Beals, Chan R ^a   Stoch, S Aubrey ^a   Steinberg, Helmut O ^a   Kelley, David E ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

^b Merck Sharp and Dohme   (Belgium)

Author keywords

Diabetes; Exenatide; Graded glucose infusion; Hyperglycemic clamp; Liraglutide; Nonobese; Obese

Indexed keywords

C PEPTIDE; EXENDIN 4; GLUCOSE; INSULIN; LIRAGLUTIDE;

ARTICLE; CLINICAL ARTICLE; COMPARATIVE STUDY; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOUBLE BLIND PROCEDURE; GLUCOSE BLOOD LEVEL; GLUCOSE INFUSION; GRADED GLUCOSE INFUSION; HUMAN; HYPERGLYCEMIA; HYPERGLYCEMIC CLAMP TECHNIQUE; INSULIN BLOOD LEVEL; INSULIN RELEASE; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; PANCREAS ISLET BETA CELL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SINGLE DRUG DOSE; STEADY STATE; BIOLOGICAL MODEL; BLOOD; DIABETES MELLITUS; DRUG EFFECTS; GLUCOSE TOLERANCE TEST; METABOLISM; NONLINEAR SYSTEM; PLACEBO EFFECT; PROCEDURES; SECRETION (PROCESS); STATISTICAL MODEL; SURVIVAL RATE;

DIABETES MELLITUS; DOUBLE-BLIND METHOD; GLUCOSE; GLUCOSE TOLERANCE TEST; HUMANS; INSULIN; INSULIN-SECRETING CELLS; LINEAR MODELS; MODELS, BIOLOGICAL; NONLINEAR DYNAMICS; OBESITY; PLACEBO EFFECT; SURVIVAL RATE;

EID: 84983652261     PISSN: 01931849     EISSN: 15221555     Source Type: Journal    
DOI: 10.1152/ajpendo.00527.2015     Document Type: Article

References (35)

1. Bergman RN, Phillips LS, Cobelli C. Physiologic evaluation of factors controlling glucose tolerance in man: measurement of insulin sensing and beta-cell glucose sensing from the response to intravenous glucose. J Clin Invest 68: 1456–1467, 1981.
2. Blonde L, Russell-Jones D. The safety and efficacy of liraglutide with or without oral antidiabetic drug therapy in type 2 diabetes: an overview of the LEAD 1–5 studies. Diabetes Obes Metab 11, Suppl 3: 26–34, 2009.
3. Brandt A, Katschinski M, Arnold R, Polonsky KS, Göke B, Byrne MM. GLP-1-induced alterations in the glucose-stimulated insulin secretory dose-response curve. Am J Physiol Endocrinol Metab 281: E242–E247, 2001.
4. Byrne MM, Sturis J, Clément K, Vionnet N, Pueyo ME, Stoffel M, Takeda J, Passa P, Cohen D, Bell GI, Velho G, Froguel P, Polonsky KS. Insulin secretory abnormalities in subjects with hyperglycemia due to glucokinase mutations. J Clin Invest 93: 1120–1130, 1994.
5. Byrne MM, Sturis J, Fajans SS, Ortiz FJ, Stoltz A, Stoffel M, Smith MJ, Bell GI, Halter JB, Polonsky KS. Altered insulin secretory responses to glucose in subjects with a mutation in the MODY1 gene on chromosome 20. Diabetes 44: 699–704, 1995.
6. Byrne MM, Sturis J, Menzel S, Yamagata K, Fajans SS, Dronsfield MJ, Bain SC, Hattersley AT, Velho G, Froguel P, Bell GI, Polonsky KS. Altered insulin secretory responses to glucose in diabetic and nondiabetic subjects with mutations in the diabetes susceptibility gene MODY3 on chromosome 12. Diabetes 45: 1503–1510, 1996.
7. Byrne MM, Sturis J, Polonsky KS. Insulin secretion and clearance during low-dose graded glucose infusion. Am J Physiol Endocrinol Metab 268: E21–E27, 1995.
8. Cerasi E, Luft R, Efendic S. Decreased sensitivity of the pancreatic beta-cels to glucose in prediabetic and diabetic subjects. A glucose dose-response study. Diabetes 21: 224–234, 1972.
9. Cersosimo E, Solis-Herrera C, Trautmann ME, Malloy J, Triplitt CL. Assessment of pancreatic beta-cell function: review of methods and clinical applications. Curr Diabetes Rev 10: 2–42, 2014.
10. Chang AM, Jakobsen G, Sturis J, Smith MJ, Bloem CJ, An B, Galecki A, Halter JB. The GLP-1 derivative NN2211 restores beta-cell sensing to glucose in type 2 diabetic patients after a single dose. Diabetes 52: 1786–1791, 2003.
11. Cobelli C, Dalla Man C, Toffolo G, Basu R, Vella A, Rizza R. The oral minimal model method. Diabetes 63: 1203–1213, 2014.
12. Cobelli C, Toffolo GM, Dalla Man C, Campioni M, Denti P, Caumo A, Butler P, Rizza R. Assessment of β-cell function in humans, simultaneously with insulin sensitivity and hepatic extraction, from intravenous and oral glucose tests. Am J Physiol Endocrinol Metab 293: E1–E15, 2007.
13. DeFronzo RA, Tobin JD, Andres R. Glucose clamp technique: a method for quantifying insulin secretion and resistance. Am J Physiol Endocrinol Metab Gastrointest Physiol 237: E214–E223, 1979.
14. Degn KB, Juhl CB, Sturis J, Jakobsen G, Brock B, Chandramouli V, Rungby J, Landau BR, Schmitz O. One week’s treatment with the long-acting glucagon-like peptide 1 derivative liraglutide (NN2211) markedly improves 24-h glycemia and alpha- and beta-cell function and reduces endogenous glucose release in patients with type 2 diabetes. Diabetes 53: 1187–1194, 2004.
15. Eaton RP, Allen RC, Schade DS, Erickson KM, Standefer J. Prehepatic insulin production in man: kinetic analysis using peripheral connecting peptide behavior. J Clin Endocrinol Metab 51: 520–528, 1980.
16. Ehrmann DA, Breda E, Cavaghan MK, Bajramovic S, Imperial J, Toffolo G, Cobelli C, Polonsky KS. Insulin secretory responses to rising and falling glucose concentrations are delayed in subjects with impaired glucose tolerance. Diabetologia 45: 509–517, 2002.
17. Ehrmann DA, Sturis J, Byrne MM, Karrison T, Rosenfield RL, Polonsky KS. Insulin secretory defects in polycystic ovary syndrome. Relationship to insulin sensitivity and family history of noninsulin-dependent diabetes mellitus. J Clin Invest 96: 520–527, 1995.
18. Elahi D. In praise of the hyperglycemic clamp. A method for assessment of beta-cell sensitivity and insulin resistance. Diabetes Care 19: 278–286, 1996.
19. Grodsky GM. A threshold distribution hypothesis for packet storage of insulin and its mathematical modeling. J Clin Invest 51: 2047–2059, 1972.
20. Jones CN, Pei D, Staris P, Polonsky KS, Chen YD, Reaven GM. Alterations in the glucose-stimulated insulin secretory dose-response curve and in insulin clearance in nondiabetic insulin-resistant individuals. J Clin Endocrinol Metab 82: 1834–1838, 1997.
21. Karam JH, Grodsky GM, Ching KN, Schmid F, Burrill K, Forsham PH. “Staircase” glucose stimulation of insulin secretion in obesity. Measure of beta-cell sensitivity and capacity. Diabetes 23: 763–770, 1974.
22. Kjems LL, Holst JJ, Vølund A, Madsbad S. The influence of GLP-1 on glucose-stimulated insulin secretion: effects on beta-cell sensing in type 2 and nondiabetic subjects. Diabetes 52: 380–386, 2003.
23. Levy JC, Rudenski A, Burnett M, Knight R, Matthews DR, Turner RC. Simple empirical assessment of beta-cell function by a constant infusion of glucose test in normal and type 2 (noninsulin-dependent) diabetic subjects. Diabetologia 34: 488–499, 1991.
24. Mager DE, Abernethy DR, Egan JM, Elahi D. Exendin-4 pharmacodynamics: insights from the hyperglycemic clamp technique. J Pharmacol Exp Ther 311: 830–835, 2004.
25. Malaisse W, Malaisse-Lagae F, Wright PH. A new method for the measurement in vitro of pancreatic insulin secretion. Endocrinology 80: 99–108, 1967.
26. Pfeifer MA, Halter JB, Porte D Jr.. Insulin secretion in diabetes mellitus. Am J Med 70: 579–588, 1981.
27. Polonsky KS, Given BD, Hirsch L, Shapiro ET, Tillil H, Beebe C, Galloway JA, Frank BH, Karrison T, Van Cauter E. Quantitative study of insulin secretion and clearance in normal and obese subjects. J Clin Invest 81: 435–441, 1988.
28. Polonsky KS, Given BD, Hirsch LJ, Tillil H, Shapiro ET, Beebe C, Frank BH, Galloway JA, Van Cauter E. Abnormal patterns of insulin secretion in noninsulin-dependent diabetes mellitus. N Engl J Med 318: 1231–1239, 1988.
29. Porte D Jr. Banting lecture 1990. Beta-cells in type II diabetes mellitus. Diabetes 40: 166–180, 1991.
30. Robertson RP, Porte D Jr.. The glucose receptor. A defective mechanism in diabetes mellitus distinct from the β-adrenergic receptor. J Clin Invest 52: 870–876, 1973.
31. Shapiro ET, Van Cauter E, Tillil H, Given BD, Hirsch L, Beebe C, Rubenstein AH, Polonsky KS. Glyburide enhances the responsiveness of the beta-cell to glucose but does not correct the abnormal patterns of insulin secretion in noninsulin-dependent diabetes mellitus. J Clin Endocrinol Metab 69: 571–576, 1989.
32. Toffolo G, Breda E, Cavaghan MK, Ehrmann DA, Polonsky KS, Cobelli C. Quantitative indexes of β-cell function during graded up& down glucose infusion from C-peptide minimal models. Am J Physiol Endocrinol Metab 280: E2–E10, 2001.
33. Turner RC, Harris E, Ounsted M, Ponsford C. Two abnormalities of glucose-induced insulin secretion: dose-response characteristics and insulin sensitivity. Acta Endocrinol (Copenh) 92: 148–165, 1979.
34. Van Cauter E, Mestrez F, Sturis J, Polonsky KS. Estimation of insulin secretion rates from C-peptide levels. Comparison of individual and standard kinetic parameters for C-peptide clearance. Diabetes 41: 368–377, 1992.
35. Van der Wal PS, Draeger KE, van Iperen AM, Martini C, Aarsen M, Heine RJ. Beta-cell response to oral glimepiride administration during and following a hyperglycaemic clamp in NIDDM patients. Diabet Med 14: 556–563, 1997.